Noble Capital Markets has initiated coverage of NeuroSense Therapeutics with an “outperform” rating and a target price of $9 per share. Thus, it estimates the micro-cap developer of an amyotrophic lateral sclerosis therapy could rise 620% from current levels. The analysts cite mid-stage trial results of the company’s lead drug PrimeC, which open the way for accelerated registration and earlier commercialization.

Details

According to the Noble initiation report published on October 14, the $9 per share target implies 620% upside from current quotes: yesterday, October 20, NeuroSense shares closed at $1.25 apiece, up 5% for the day.

Nevertheless, Noble’s valuation is among the most conservative on Wall Street, MarketWatch data shows. The average target price from three analysts covering the company is $11.50 per share, implying upside of 820% from the closing price yesterday. NeuroSense has two “buy” ratings versus one “hold."

Noble's rationale

NeuroSense is developing drugs to treat neurodegenerative diseases. Its lead candidate, PrimeC, is designed as a therapy for amyotrophic lateral sclerosis (ALS), an incurable progressive disease that destroys motor neurons, leading to paralysis and death.

Two phase II trials showed that PrimeC can slow disease progression and improve survival. A phase III trial is scheduled to start in 2026, which, according to Noble, implies potential U.S. market entry in 2029. At the same time, the drug could reach the market earlier in Canada as early as 2027, since the country allows accelerated approval of therapies for life-threatening diseases without completion of the final phase of trials.

In addition to its ALS program, NeuroSense is also developing therapies for Alzheimer’s disease (in phase II testing) and Parkinson’s disease (not yet in clinical trials). However, Noble did not include these programs in its valuation model, the analysts note.

The AI translation of this story was reviewed by a human editor.

Share